Molecular changes in the progression of Barrett's oesophagus

Postgraduate Medical Journal

Volumn 83, Issue 982, 2007, Pages 529-535

  Zagorowicz, Edyta ^b   Jankowski, Janusz ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; PROTON PUMP INHIBITOR; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN;

ANEUPLOIDY; APOPTOSIS; BARRETT ESOPHAGUS; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; DISEASE COURSE; DYSPLASIA; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; METAPLASIA; MOLECULAR BIOLOGY; REVIEW; TREATMENT RESPONSE;

ANEUPLOIDY; APOPTOSIS; BARRETT ESOPHAGUS; CADHERINS; CELL CYCLE; CELL PROLIFERATION; CYCLOOXYGENASE 2; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; HUMANS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548153062     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.052910     Document Type: Review

References (84)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-7.
2. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
3. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
4. Jankowski J, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588-90.
5. Coebergh J, Sant M, Berrini F, et al. Survival of adult cancer patients in Europe diagnosed from 1978-1989. Eur J Cancer 1998;34(supplements [1359-6349]):2137.
6. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54(Suppl 1):i1-5.
7. Chak A, Lee T, Kinnard MF, et al. Caucasian adults oesophagogastric junctional adenocarcinoma in oesophageal adenocarcinoma, and familial aggregation of Barrett's oesophagus. Gut 2002;51:323-8.
8. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's oesophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004;99:1557-66.
9. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/ NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
10. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development dysplasia in patients with Barrett's esophagus. Med J Aust 2004;180:387-91.
11. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.
12. Kelloff GJ, Sigman CC, Johnson KM, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epid Biom Prev 2000;9:127-37.
13. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Ntl Cancer Inst 2001;93:1054-61.
14. Silberg DG, Swain GP, Suh ER, et al. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000;119:961-71.
15. Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A 2005;102:7565-70.
16. Kazumori H, Ishihara S, Rumi MA, et al. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006;55:16-25.
17. Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol Hepatol 2002;37:94-100.
18. Phillips RW, Frierson HF, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-7.
19. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004;57:1063-8.
20. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
21. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369-97.
22. Hanahan DWR. The hallmarks of cancer. Cell 2000;100:57-70.
23. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
24. Maley CC, Galipeau CC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33.
25. Wong DJ, Barrett MT, Stoger R, et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997;57:2619-22.
26. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Research 2000;60:5021-6.
27. Bian YS, Osterheld MC, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21.
28. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
29. Bani-Hani K, Martin TC, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
30. Herbst JJ, BBerenson MM, McCloskey DW, et al. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 1978;75:683-7.
31. Gray MR, Hall PA, Nash J, et al. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
32. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
33. Reid BJ, Haggitt RC, Rubin CE, et al. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
34. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytomerric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102(4 Pt 1):1212-9.
35. Shay JW, Bacchetti S, A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
36. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83:652-9.
37. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-42.
38. Kim NW, Wu F, Advances in quantification, characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997;25:2595-7.
39. Going JJ, Fletcher-Monagha AJ, Neilson L, et al. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett's esophagus. Neoplasia 2004;6:85-92.
40. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
41. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/ tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. PNAS 1996;93:7081-4.
42. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high risk patient subsets. Am J Gastroenterol 2000;95:669-76.
43. Rabinowitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
44. Muzeau F, Flejou JF, Potet F, et al. Profile of p53 mutations and abnormal expression of P53 protein in 2 forms of esophageal cancer. Gastroenterol Clin Biol 1996;20:430-7.
45. Campomenosi P, Conio M, Bogliolo M, et al. p53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 1996;5:559-65.
46. Kubba AK, Poole NA, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999;44:659-67.
47. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
48. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
49. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
50. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-10.
51. Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol 1995;90:1808-13.
52. Bailey T, Biddlestone L, Shepherd N, et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia- adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-44.
53. selepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-81.
54. Thun MJ, Henely SJ, Patrono C. Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002;94:252-66.
55. Wilson KT, Fu S, Ramanujam KS, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated carcinomas. Cancer Res 1998;58:2929-34.
56. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-aysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
57. hirvani VN, Ouaru-Lascar R, Kaur BS, et al. Cyclooxygenase-2 expression in Barrett's oesophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterol Clin Biol 2000;118:487-96.
58. Buskens CJ, van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1808-7.
59. Wijnhoven BP, de Both NJ, van Dekken H, et al. E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus. Br J Cancer 1999;80:1652-7.
60. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
61. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
62. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-9.
63. Finch PW, He X, Kelley MJ, et al. Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA 2003;94:6770-5.
64. Zou H, Molina JF, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005;116:584- 91.
65. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;54:931-68.
66. Folk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170-6.
67. van Sandick JW, van Lanschott JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
68. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
69. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
70. Buttar NS, Wong KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
71. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
72. Sharma P. Barrett's esophagus: from process to outcomes. Am J Gastroenterol 2001;96:624-6.
73. Weston AP, Banerjee S, Sharma P, et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
74. Sharma P, Falk G, Weston A, et al. Natural history of low grade dysplasia - an infrequent finding which usually regresses-preliminary results from the Barrett's esophagus study. Gastroenterology 2002;122:A20.
75. Jankowski J, Moayyadi PR. Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004;96:885-7.
76. Jankowski J, Zagorowicz E. Chemoprevention for Barrett's esophagus. Barrett's esophagus and adenocarcinoma of the esophagus. Oxford: Blackwell Publishing, 2006:236-52.
77. Lagorce C, Paraf F, Vidaud D, et al. Cyclooxygenase-2 is expressed frequently ana early in Barrett's esophagus and associated adenocarcinoma. Histopathology 2003;42:457-65.
78. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferafion in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G327- 34.
79. Siriex PS, O'Donovan M, Brown J, et al. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2003;7:2560-6.
80. Mitas M, Almeida J, Mikhitarian K, et al. Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res 2005;11:2205-14.
81. Chang Y, Gong J, Liu B, et al. Gene expression profiling in Barrett's esophagus and cardia intestinal metaplasia: a comparative analysis using cDNA microarray. World J Gastroenterol 2004;10:3194-6.
82. Helm J, Enkemann SA, Coppola D, et al. Dedifferenriation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res 2005;11:2478-85.
83. Streitz JM, Madden MT, Marimanikkuppam SS, et al. Analysis of protein expression patterns in Barrett's esophagus using MALDI mass spectrometry, in search of malignancy biomarkers. Dis Esophagus 2005;18:170-6.
84. McShane LM, Altman DG, Sauerbrei W, et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.